HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011

for the NHBS study group

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Men who have sex with men (MSM) are at high risk for disease associated with human papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Among 3221 MSM aged 18-26, 157 (4.9%) reported ≥1 vaccine dose. Uptake was higher among men who visited a healthcare provider (aPR 2.3, CI: 1.2-4.2), disclosed same-sex sexual attraction/behavior to a provider (aPR 2.1, CI: 1.3-3.3), reported a positive HIV test (aPR 2.2, CI: 1.5-3.2), or received hepatitis vaccine (aPR 3.9, CI: 2.4-6.4). Of 3064 unvaccinated MSM, 2326 (75.9%) had visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among MSM provide a baseline as vaccination recommendations are implemented.

Original languageEnglish (US)
Pages (from-to)6356-6359
Number of pages4
JournalVaccine
Volume32
Issue number48
DOIs
StatePublished - Nov 12 2014
Externally publishedYes

Fingerprint

Papillomavirus Vaccines
Papillomaviridae
confidence interval
HIV
Confidence Intervals
vaccines
monitoring
gender
Sexual Behavior
Health Personnel
health services
Vaccines
hepatitis
Hepatitis
multivariate analysis
Vaccination
Multivariate Analysis
vaccination
dosage
testing

Keywords

  • Human papillomavirus (HPV)
  • Men who have sex with men (MSM)
  • Vaccine uptake

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011. / for the NHBS study group.

In: Vaccine, Vol. 32, No. 48, 12.11.2014, p. 6356-6359.

Research output: Contribution to journalArticle

@article{fb63c25f8d5c4846b2649f6b6dc1e0c4,
title = "HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011",
abstract = "Men who have sex with men (MSM) are at high risk for disease associated with human papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis to calculate adjusted prevalence ratios (aPRs) and 95{\%} confidence intervals (CIs). Among 3221 MSM aged 18-26, 157 (4.9{\%}) reported ≥1 vaccine dose. Uptake was higher among men who visited a healthcare provider (aPR 2.3, CI: 1.2-4.2), disclosed same-sex sexual attraction/behavior to a provider (aPR 2.1, CI: 1.3-3.3), reported a positive HIV test (aPR 2.2, CI: 1.5-3.2), or received hepatitis vaccine (aPR 3.9, CI: 2.4-6.4). Of 3064 unvaccinated MSM, 2326 (75.9{\%}) had visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among MSM provide a baseline as vaccination recommendations are implemented.",
keywords = "Human papillomavirus (HPV), Men who have sex with men (MSM), Vaccine uptake",
author = "{for the NHBS study group} and Elissa Meites and Markowitz, {Lauri E.} and Gabriela Paz-Bailey and Oster, {Alexandra M.} and Jianglan White and Jeff Todd and Greg Bautista and Colin Flynn and Danielle German and Maura Miminos and Rose Doherty and Chris Wittke and Nikhil Prachand and Nanette Benbow and Sharon Melville and Shane Sheu and Alicia Novoa and Mark Thrun and Alia Al-Tayyib and Ralph Wilmoth and Vivian Griffin and Emily Higgins and Karen MacMaster and Marcia Wolverton and Hafeez Rehman and Paige Padgett and Trista Bingham and Sey, {Ekow Kwa} and Marlene LaLota and Lisa Metsch and Forrest, {David W} and Anderson, {Bridget J.} and Watson, {Carol Ann} and Lou Smith and DeAnn Gruber and Robinson, {William T.} and Narquis Barak and Alan Neai-gus and Reilly, {Kathleen H.} and Travis Wendel and Barbara Bolden and Afework Wogayehu and Henry Godette and Brady, {Kathleen A.} and Andrea Sifferman and Vanessa Miguelino-Keasling and Al Velasco and Veronica Tovar and Raymond, {H. Fisher} and {De Le{\'o}n}, {Sandra Miranda}",
year = "2014",
month = "11",
day = "12",
doi = "10.1016/j.vaccine.2014.09.033",
language = "English (US)",
volume = "32",
pages = "6356--6359",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "48",

}

TY - JOUR

T1 - HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011

AU - for the NHBS study group

AU - Meites, Elissa

AU - Markowitz, Lauri E.

AU - Paz-Bailey, Gabriela

AU - Oster, Alexandra M.

AU - White, Jianglan

AU - Todd, Jeff

AU - Bautista, Greg

AU - Flynn, Colin

AU - German, Danielle

AU - Miminos, Maura

AU - Doherty, Rose

AU - Wittke, Chris

AU - Prachand, Nikhil

AU - Benbow, Nanette

AU - Melville, Sharon

AU - Sheu, Shane

AU - Novoa, Alicia

AU - Thrun, Mark

AU - Al-Tayyib, Alia

AU - Wilmoth, Ralph

AU - Griffin, Vivian

AU - Higgins, Emily

AU - MacMaster, Karen

AU - Wolverton, Marcia

AU - Rehman, Hafeez

AU - Padgett, Paige

AU - Bingham, Trista

AU - Sey, Ekow Kwa

AU - LaLota, Marlene

AU - Metsch, Lisa

AU - Forrest, David W

AU - Anderson, Bridget J.

AU - Watson, Carol Ann

AU - Smith, Lou

AU - Gruber, DeAnn

AU - Robinson, William T.

AU - Barak, Narquis

AU - Neai-gus, Alan

AU - Reilly, Kathleen H.

AU - Wendel, Travis

AU - Bolden, Barbara

AU - Wogayehu, Afework

AU - Godette, Henry

AU - Brady, Kathleen A.

AU - Sifferman, Andrea

AU - Miguelino-Keasling, Vanessa

AU - Velasco, Al

AU - Tovar, Veronica

AU - Raymond, H. Fisher

AU - De León, Sandra Miranda

PY - 2014/11/12

Y1 - 2014/11/12

N2 - Men who have sex with men (MSM) are at high risk for disease associated with human papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Among 3221 MSM aged 18-26, 157 (4.9%) reported ≥1 vaccine dose. Uptake was higher among men who visited a healthcare provider (aPR 2.3, CI: 1.2-4.2), disclosed same-sex sexual attraction/behavior to a provider (aPR 2.1, CI: 1.3-3.3), reported a positive HIV test (aPR 2.2, CI: 1.5-3.2), or received hepatitis vaccine (aPR 3.9, CI: 2.4-6.4). Of 3064 unvaccinated MSM, 2326 (75.9%) had visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among MSM provide a baseline as vaccination recommendations are implemented.

AB - Men who have sex with men (MSM) are at high risk for disease associated with human papillomavirus (HPV). In late 2011, HPV vaccine was recommended for males through age 21 and MSM through age 26. Using data from the 2011 National HIV Behavioral Surveillance System, we assessed self-reported HPV vaccine uptake among MSM, using multivariate analysis to calculate adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs). Among 3221 MSM aged 18-26, 157 (4.9%) reported ≥1 vaccine dose. Uptake was higher among men who visited a healthcare provider (aPR 2.3, CI: 1.2-4.2), disclosed same-sex sexual attraction/behavior to a provider (aPR 2.1, CI: 1.3-3.3), reported a positive HIV test (aPR 2.2, CI: 1.5-3.2), or received hepatitis vaccine (aPR 3.9, CI: 2.4-6.4). Of 3064 unvaccinated MSM, 2326 (75.9%) had visited a healthcare provider within 1 year. These national data on HPV vaccine uptake among MSM provide a baseline as vaccination recommendations are implemented.

KW - Human papillomavirus (HPV)

KW - Men who have sex with men (MSM)

KW - Vaccine uptake

UR - http://www.scopus.com/inward/record.url?scp=84908620131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908620131&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2014.09.033

DO - 10.1016/j.vaccine.2014.09.033

M3 - Article

VL - 32

SP - 6356

EP - 6359

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 48

ER -